Literature DB >> 24918566

Incorrect reconstitution of incobotulinumtoxinA leads to loss of neurotoxin.

Wayne D Carey.   

Abstract

BACKGROUND: IncobotulinumtoxinA (INCO) was approved for aesthetic use in the United States in 2011. When reconstituted per manufacturer's instructions, diminished delivery of INCO in US may result.
OBJECTIVE: Investigators sought to determine whether potential loss of decreased motor activity could be demonstrated, using a simple reconstitution technique. METHODS AND MATERIALS: In this 5-patient study, investigators added 2.0 mL of saline to INCO powder at the bottom of the first of 5 vials, swirling gently to dissolve INCO powder at the bottom. Reconstituted INCO was discarded and the cap was replaced. The "empty" vial then received 0.6 mL of saline, and was swirled and inverted 3 times to ensure dissolution. The 0.6 mL from the first vial was added to the second "empty" vial and the process was repeated for the remaining 3 vials (5 vials per patient). Patients were injected from reconstitution of "empty" vials to determine neuromodulatory activity. Pre- and post-treatment patient photographs of maximal contraction were taken.
RESULTS: Markedly diminished maximal frown could be observed in all 5 patients.
CONCLUSION: Improper reconstitution of INCO, or swirling without inversion of the vial following saline injection, can result in significant loss of units of the neurotoxin in the clinical setting.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24918566

Source DB:  PubMed          Journal:  J Drugs Dermatol        ISSN: 1545-9616            Impact factor:   2.114


  5 in total

Review 1.  Pharmacotherapy for the management of achalasia: Current status, challenges and future directions.

Authors:  Ammar Nassri; Zeeshan Ramzan
Journal:  World J Gastrointest Pharmacol Ther       Date:  2015-11-06

2.  Pharmaceutical, biological, and clinical properties of botulinum neurotoxin type A products.

Authors:  Jürgen Frevert
Journal:  Drugs R D       Date:  2015-03

Review 3.  Key Parameters for the Use of AbobotulinumtoxinA in Aesthetics: Onset and Duration.

Authors:  Mark Nestor; Glynis Ablon; Andy Pickett
Journal:  Aesthet Surg J       Date:  2017-05-01       Impact factor: 4.283

Review 4.  Botulinum neurotoxin formulations: overcoming the confusion.

Authors:  Souphiyeh Samizadeh; Koenraad De Boulle
Journal:  Clin Cosmet Investig Dermatol       Date:  2018-05-30

5.  Liquid Formulation of AbobotulinumtoxinA: A 6-Month, Phase 3, Double-Blind, Randomized, Placebo-Controlled Study of a Single Treatment, Ready-to-Use Toxin for Moderate-to-Severe Glabellar Lines.

Authors:  Benjamin Ascher; Berthold Rzany; Philippe Kestemont; Said Hilton; Marc Heckmann; Isaac Bodokh; Ernst Magnus Noah; Dominique Boineau; Martina Kerscher; Magali Volteau; Philippe Le Berre; Philippe Picaut
Journal:  Aesthet Surg J       Date:  2020-01-01       Impact factor: 4.283

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.